1. Home
  2. EDSA vs POLA Comparison

EDSA vs POLA Comparison

Compare EDSA & POLA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • EDSA
  • POLA
  • Stock Information
  • Founded
  • EDSA 2015
  • POLA 1979
  • Country
  • EDSA Canada
  • POLA United States
  • Employees
  • EDSA N/A
  • POLA N/A
  • Industry
  • EDSA Biotechnology: Pharmaceutical Preparations
  • POLA Industrial Machinery/Components
  • Sector
  • EDSA Health Care
  • POLA Miscellaneous
  • Exchange
  • EDSA Nasdaq
  • POLA Nasdaq
  • Market Cap
  • EDSA 6.2M
  • POLA 5.6M
  • IPO Year
  • EDSA N/A
  • POLA 2016
  • Fundamental
  • Price
  • EDSA $1.83
  • POLA $1.73
  • Analyst Decision
  • EDSA Strong Buy
  • POLA
  • Analyst Count
  • EDSA 1
  • POLA 0
  • Target Price
  • EDSA $21.00
  • POLA N/A
  • AVG Volume (30 Days)
  • EDSA 35.8K
  • POLA 9.3K
  • Earning Date
  • EDSA 05-14-2025
  • POLA 05-16-2025
  • Dividend Yield
  • EDSA N/A
  • POLA N/A
  • EPS Growth
  • EDSA N/A
  • POLA N/A
  • EPS
  • EDSA N/A
  • POLA N/A
  • Revenue
  • EDSA N/A
  • POLA $13,918,000.00
  • Revenue This Year
  • EDSA N/A
  • POLA N/A
  • Revenue Next Year
  • EDSA N/A
  • POLA N/A
  • P/E Ratio
  • EDSA N/A
  • POLA N/A
  • Revenue Growth
  • EDSA N/A
  • POLA 8.08
  • 52 Week Low
  • EDSA $1.55
  • POLA $1.68
  • 52 Week High
  • EDSA $5.59
  • POLA $4.90
  • Technical
  • Relative Strength Index (RSI)
  • EDSA 29.28
  • POLA 33.67
  • Support Level
  • EDSA $1.88
  • POLA $1.77
  • Resistance Level
  • EDSA $2.05
  • POLA $1.87
  • Average True Range (ATR)
  • EDSA 0.08
  • POLA 0.06
  • MACD
  • EDSA -0.00
  • POLA 0.01
  • Stochastic Oscillator
  • EDSA 0.00
  • POLA 26.32

About EDSA Edesa Biotech Inc.

Edesa Biotech Inc is a biotechnology company focused on inflammatory and immune-related diseases. It is involved in exploring novel ways to treat these diseases, including alternatives to topical steroids, which can have side effects. The company's product candidate, EB06, is an anti-CXCL10 monoclonal antibody candidate and is being developed as a therapy for vitiligo, a common autoimmune disorder that causes the skin to lose its color in patches. The other drug candidates in its product pipeline include EB05, EB07, and EB01 which are in their different phases of development.

About POLA Polar Power Inc.

Polar Power Inc is engaged in designing, manufacturing, and selling DC power generators, renewable energy, and cooling systems for applications in the telecommunications market and, to a lesser extent, in other markets, including military, electric vehicle, marine, and industrial. The company's products include DC generators, backup DC generators, hybrid power systems, Li-Ion battery systems, Marine DC generators, and others. The company's geographical presence is in the United States, Canada, Australia and South Pacific Islands, Asia, Europe and Middle East, United Kingdom, Other North America, South Africa, and others.

Share on Social Networks: